Details for Patent: 12,740,970
Which drugs does patent 12,740,970 protect, and when does it expire?
Patent 12,740,970 protects HYFTOR and is included in one NDA.
This patent has three patent family members in two countries.
Drugs Protected by US Patent 12,740,970
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nobelpharma | HYFTOR | sirolimus | GEL;TOPICAL | 213478-001 | Mar 22, 2022 | RX | Yes | Yes | 12,740,970 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,740,970
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Germany | 102023119976 | ⤷ Start Trial | |||
| United Kingdom | 202316245 | ⤷ Start Trial | |||
| United Kingdom | 2632174 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
